KZR vs. TARA, PLX, RAPT, NKTX, NMRA, THTX, CTNM, KYTX, EXOZ, and ATOS
Should you be buying Kezar Life Sciences stock or one of its competitors? The main competitors of Kezar Life Sciences include Protara Therapeutics (TARA), Protalix BioTherapeutics (PLX), RAPT Therapeutics (RAPT), Nkarta (NKTX), Neumora Therapeutics (NMRA), Theratechnologies (THTX), Contineum Therapeutics (CTNM), Kyverna Therapeutics (KYTX), Exozymes (EXOZ), and Atossa Therapeutics (ATOS). These companies are all part of the "pharmaceutical products" industry.
Kezar Life Sciences vs. Its Competitors
Kezar Life Sciences (NASDAQ:KZR) and Protara Therapeutics (NASDAQ:TARA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability, community ranking and analyst recommendations.
Kezar Life Sciences has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500. Comparatively, Protara Therapeutics has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500.
Protara Therapeutics has lower revenue, but higher earnings than Kezar Life Sciences. Protara Therapeutics is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks.
Kezar Life Sciences currently has a consensus target price of $39.50, indicating a potential upside of 724.63%. Protara Therapeutics has a consensus target price of $20.50, indicating a potential upside of 528.83%. Given Kezar Life Sciences' higher probable upside, analysts clearly believe Kezar Life Sciences is more favorable than Protara Therapeutics.
In the previous week, Protara Therapeutics had 6 more articles in the media than Kezar Life Sciences. MarketBeat recorded 7 mentions for Protara Therapeutics and 1 mentions for Kezar Life Sciences. Kezar Life Sciences' average media sentiment score of 1.89 beat Protara Therapeutics' score of 1.21 indicating that Kezar Life Sciences is being referred to more favorably in the media.
Kezar Life Sciences received 95 more outperform votes than Protara Therapeutics when rated by MarketBeat users. However, 70.00% of users gave Protara Therapeutics an outperform vote while only 57.08% of users gave Kezar Life Sciences an outperform vote.
67.9% of Kezar Life Sciences shares are held by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are held by institutional investors. 10.4% of Kezar Life Sciences shares are held by insiders. Comparatively, 8.4% of Protara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Kezar Life Sciences' return on equity of -54.95% beat Protara Therapeutics' return on equity.
Summary
Kezar Life Sciences beats Protara Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Kezar Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for KZR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding KZR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kezar Life Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:KZR) was last updated on 6/13/2025 by MarketBeat.com Staff
